315 related articles for article (PubMed ID: 33480665)
21. Ceftobiprole: drug evaluation and place in therapy.
Giacobbe DR; De Rosa FG; Del Bono V; Grossi PA; Pea F; Petrosillo N; Rossolini GM; Tascini C; Tumbarello M; Viale P; Bassetti M
Expert Rev Anti Infect Ther; 2019 Sep; 17(9):689-698. PubMed ID: 31553250
[No Abstract] [Full Text] [Related]
22. A Randomized, Prospective Study of Pediatric Patients With Community-acquired Pneumonia Treated With Ceftaroline Versus Ceftriaxone.
Cannavino CR; Nemeth A; Korczowski B; Bradley JS; O'Neal T; Jandourek A; Friedland HD; Kaplan SL
Pediatr Infect Dis J; 2016 Jul; 35(7):752-9. PubMed ID: 27093162
[TBL] [Abstract][Full Text] [Related]
23. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens.
Jantausch BA; Deville J; Adler S; Morfin MR; Lopez P; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S164-71. PubMed ID: 14520142
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic and pharmacodynamics evaluation of ceftobiprole medocaril for the treatment of hospital-acquired pneumonia.
Lagacé-Wiens PR; Rubinstein E
Expert Opin Drug Metab Toxicol; 2013 Jun; 9(6):789-99. PubMed ID: 23590397
[TBL] [Abstract][Full Text] [Related]
25. A
Huang H; Gao L; Engelhardt M; Saulay M; Hamed K
Future Microbiol; 2021 Jul; 16():783-796. PubMed ID: 34155899
[TBL] [Abstract][Full Text] [Related]
26. FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.
Low DE; File TM; Eckburg PB; Talbot GH; David Friedland H; Lee J; Llorens L; Critchley IA; Thye DA;
J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii33-44. PubMed ID: 21482568
[TBL] [Abstract][Full Text] [Related]
27. Ceftobiprole: a new broad spectrum cephalosporin.
El Solh A
Expert Opin Pharmacother; 2009 Jul; 10(10):1675-86. PubMed ID: 19527192
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of ceftobiprole in patients aged 65 years or older: a
Welte T; Scheeren TW; Overcash JS; Saulay M; Engelhardt M; Hamed K
Future Microbiol; 2021 May; 16():543-555. PubMed ID: 33960817
[TBL] [Abstract][Full Text] [Related]
29. A comparison of cefditoren pivoxil and amoxicillin/ clavulanate in the treatment of community-acquired pneumonia: a multicenter, prospective, randomized, investigator-blinded, parallel-group study.
Fogarty CM; Cyganowski M; Palo WA; Hom RC; Craig WA
Clin Ther; 2002 Nov; 24(11):1854-70. PubMed ID: 12501879
[TBL] [Abstract][Full Text] [Related]
30. A Multicenter, Randomized, Observer-blinded, Active-controlled Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Comparator in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infection.
Korczowski B; Antadze T; Giorgobiani M; Stryjewski ME; Jandourek A; Smith A; O'Neal T; Bradley JS
Pediatr Infect Dis J; 2016 Aug; 35(8):e239-47. PubMed ID: 27164462
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic drug evaluation of ceftobiprole for the treatment of MRSA.
Horn KS; Danziger LH; Rodvold KA; Glowacki RC
Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):463-472. PubMed ID: 28264613
[TBL] [Abstract][Full Text] [Related]
32. Integrated safety summary of FOCUS 1 and FOCUS 2 trials: Phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia.
Rank DR; Friedland HD; Laudano JB
J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii53-9. PubMed ID: 21482570
[TBL] [Abstract][Full Text] [Related]
33. Safety and tolerability of ceftobiprole.
Grau S
Rev Esp Quimioter; 2019 Sep; 32 Suppl 3(Suppl 3):34-36. PubMed ID: 31364340
[TBL] [Abstract][Full Text] [Related]
34. Pharmacodynamic profiling of ceftobiprole for treatment of complicated skin and skin structure infections.
Kimko H; Xu X; Nandy P; Samtani MN; Strauss RS; Bagchi P; Noel GJ
Antimicrob Agents Chemother; 2009 Aug; 53(8):3371-4. PubMed ID: 19528285
[TBL] [Abstract][Full Text] [Related]
35. Ceftobiprole: an extended-spectrum anti-methicillin-resistant Staphylococcus aureus cephalosporin.
Anderson SD; Gums JG
Ann Pharmacother; 2008 Jun; 42(6):806-16. PubMed ID: 18477729
[TBL] [Abstract][Full Text] [Related]
36. Ceftobiprole medocaril (BAL5788) treatment of experimental Haemophilus influenzae, Enterobacter cloacae, and Klebsiella pneumoniae murine pneumonia.
Rouse MS; Hein MM; Anguita-Alonso P; Steckelberg JM; Patel R
Diagn Microbiol Infect Dis; 2006 Aug; 55(4):333-6. PubMed ID: 16631339
[TBL] [Abstract][Full Text] [Related]
37. Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA).
Barbour A; Schmidt S; Rand KH; Derendorf H
Int J Antimicrob Agents; 2009 Jul; 34(1):1-7. PubMed ID: 19261449
[TBL] [Abstract][Full Text] [Related]
38. Possible clinical indications of ceftobiprole.
Barberán J
Rev Esp Quimioter; 2019 Sep; 32 Suppl 3(Suppl 3):29-33. PubMed ID: 31364339
[TBL] [Abstract][Full Text] [Related]
39. A Phase II Randomized, Double-blind, Multicenter Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Vancomycin for the Treatment of Nosocomial Pneumonia Suspected or Confirmed to be Due to Gram-positive Pathogens.
Huang DB; File TM; Torres A; Shorr AF; Wilcox MH; Hadvary P; Dryden M; Corey GR
Clin Ther; 2017 Aug; 39(8):1706-1718. PubMed ID: 28756068
[TBL] [Abstract][Full Text] [Related]
40. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia.
Wunderink RG; Cammarata SK; Oliphant TH; Kollef MH;
Clin Ther; 2003 Mar; 25(3):980-92. PubMed ID: 12852712
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
